PURPOSE: To determine the accuracy of combined magnetic resonance (MR) imaging and three-dimensional (3D) proton MR spectroscopic imaging in @entity263 to a sextant of the gland in @entity1 receiving hormone deprivation therapy. MATERIALS AND METHODS: Combined MR imaging/3D MR spectroscopic imaging examinations were performed in 16 hormone-treated @entity1 and 48 nontreated matched control @entity1 before radical prostatectomy and step-section histopathologic analysis. At MR imaging, @entity5 presence within the peripheral zone was assessed on a per sextant basis by two readers. @entity5582 MR spectroscopic imaging, @entity5 was identified by using ( @entity1877 plus @entity908 )-to- @entity1792 ratios at cutoff values of 2 and 3 SDs above mean normal peripheral zone values. Data were compared by using receiver operating characteristic analysis. RESULTS: There was no significant difference in the ability of combined MR imaging/3D MR spectroscopic imaging to @entity263 in treated versus control @entity1 . For MR imaging alone, the sensitivity and specificity were 91% and 48% (reader 1) and 75% and 60% (reader 2) in treated @entity1 versus 79% and 60% (reader 1) and 84% and 43% (reader 2) in control @entity1 . For 3D MR spectroscopic imaging alone (>3 SDs cutoff), higher specificity (treated, 80%; controls, 73%) but lower sensitivity (treated, 56%; controls, 53%) was attained. In treated @entity1 , high sensitivity or specificity (up to 92%) was achieved when either or both modalities indicated @entity5 . CONCLUSION: When performed within 4 months after initiating hormone deprivation therapy, combined MR imaging/3D MR spectroscopic imaging had the same accuracy in @entity263 as in nontreated @entity1 .

XXXX : effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localize prostate cancer', 'localizing prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine'] @entity1792 :: ('MESH:D019343', 'Chemical') :: ['citrate'] @entity1877 :: ('MESH:D002794', 'Chemical') :: ['choline'] @entity5582 :: ('462', 'Gene') :: ['At 3D']
@entity263 :: (MESH:D011471,Disease) :: ['Localized prostate cancer']
